- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07716228
Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound (ADGP Ⅱ)
16. Juli 2026 aktualisiert von: Second Affiliated Hospital, School of Medicine, Zhejiang University
Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound in Pancreatic Cancer Treatment
This study aims to evaluate whether the preventive and suppressive effects of auricular point stimulation combined with dexamethasone on nausea and vomiting induced by the gemcitabine plus paclitaxel protein-bound regimen are non-inferior to the standard antiemetic regimen in pancreatic cancer treatment.
Additionally, it will assess patients' appetite, gastrointestinal function, and other related indicators, and explore the significant role of integrated traditional Chinese medicine and Western medicine interventions in improving patients' quality of life during chemotherapy, thereby providing a clinical reference for optimizing the management of adverse reactions of this chemotherapy regimen.
The main questions it aims to answer are: Whether the preventive and suppressive effects of auricular point stimulation combined with dexamethasone on nausea and vomiting induced by the gemcitabine plus paclitaxel protein-bound regimen are non-inferior to the standard antiemetic regimen?
In comparison with a standard pharmacologic antiemetic regimen, does auricular point stimulation plus dexamethasone effectively reduce the incidence of appetite loss, weakened or disordered gastrointestinal function, and other uncomfortable conditions?
Pancreatic cancer patients receiving adjuvant or palliative chemotherapy with the gemcitabine plus paclitaxel protein-bound regimen after surgery will be randomly assigned in a 1:1 ratio to either the auricular point stimulation group or the standard pharmacologic antiemetic regimen group.
Patients in the auricular point stimulation group will: Receive auricular acupressure with bean seeds on specific points of one ear, plus intravenous injection of dexamethasone as a preventive antiemetic treatment within half an hour before chemotherapy.
Starting from the day of chemotherapy (Day 1) to the following five days (Day 1-Day 5), provide regular stimulation at the acupressure points daily by themselves according to the protocol provided in this trial.
Record their nausea and vomiting status, appetite, and gastrointestinal function-related symptomatic indicators from Day 1 to Day 5. Oral antiemetics are also prepared.
If nausea and vomiting are significant or the patient feels the need, they may be temporarily administered as an adjunct.
Patients in the standard pharmacologic antiemetic regimen group will: Receive the standard pharmacologic antiemetic regimen chosen by their physicians according to clinical guidelines.
Studienübersicht
Status
Rekrutierung
Bedingungen
Detaillierte Beschreibung
Gemcitabine combined with paclitaxel protein-bound is currently one of the commonly used chemotherapy regimens for postoperative adjuvant and palliative treatment of pancreatic cancer.
While it improves patient survival rates, it is also associated with certain gastrointestinal adverse reactions.
Chemotherapy-related nausea and vomiting are relatively common, with an incidence of approximately 10%.
The majority of these symptoms occur on the day of administration and within the following four days.
This regimen is currently classified as a low-emetogenic-risk treatment in clinical guidelines.
The recommended prophylactic antiemetic strategy typically involves corticosteroids (e.g., dexamethasone) and/or 5-HT3 receptor antagonists (e.g., ondansetron, palonosetron).
In clinical practice, single-agent antiemetic therapy often fails to effectively prevent delayed nausea and vomiting.
Consequently, most physicians opt for dual-agent antiemetic therapy.
However, excessive use of antiemetics frequently leads to drug-related gastrointestinal adverse reactions such as anorexia, bloating, constipation, and diarrhea.
Studies have shown that the incidence of constipation in chemotherapy patients treated with palonosetron nearly doubles.
The intensive use of antiemetics severely impacts patients' gastrointestinal function, quality of life, and even their treatment adherence.
Therefore, how to effectively prevent chemotherapy-induced nausea and vomiting while minimizing the side effects of antiemetic therapy itself has become a practical issue that healthcare professionals urgently need to address.
Auricular point pressotherapy is a traditional Chinese medicine (TCM) external therapy.
It involves accurately pasting Vaccaria seeds on corresponding auricular points with adhesive tapes and stimulating the points through moderate pressing to regulate physical functions and treat diseases.
According to TCM theory, the ear is closely connected to the internal organs and meridians of the human body, and all twelve meridians are directly or indirectly linked to the ear.
Auricular point pressotherapy can unblock meridians and balance yin and yang by stimulating corresponding auricular points, thereby alleviating CINV and other adverse reactions.
It is an economical, non-invasive, and low-side-effect natural therapy.
Meanwhile, auricular point pressotherapy can effectively improve gastrointestinal function, thus significantly reducing gastrointestinal dysfunction caused by chemotherapy and antiemetic drugs, such as anorexia, abdominal distension, constipation, and diarrhea.
Our team summarized the relevant data of patients who voluntarily received auricular point pressotherapy for antiemesis previously.
The results showed that among pancreatic cancer patients who received gemcitabine combined with paclitaxel protein-bound for postoperative adjuvant or palliative therapy, 100% of those treated with auricular point pressotherapy plus dexamethasone did not experience grade 2 or above (including grade 2) nausea and had no vomiting on the day of medication and within 3 days thereafter.
Based on the above theoretical and practical basis, this study intends to evaluate whether the preventive and suppressive effects of auricular point stimulation combined with dexamethasone on the CINV induced by the gemcitabine plus paclitaxel protein-bound regimen are non-inferior to the standard antiemetic regimen.
Additionally, it will assess patients' appetite, gastrointestinal function, and other related indicators, and explore the significant role of integrated traditional Chinese medicine and Western medicine interventions in improving patients' quality of life during chemotherapy, thereby providing a clinical reference for optimizing the management of adverse reactions of this chemotherapy regimen.
Studientyp
Interventionell
Einschreibung (Geschätzt)
74
Phase
- Phase 3
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Juan Wang
- Telefonnummer: 8617816190946
- E-Mail: wangjuan.happy@hotmail.com
Studienorte
-
-
-
Hangzhou, China
- Rekrutierung
- Second Affiliated Hospital of Zhejiang University School of Medicine
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Nein
Beschreibung
Inclusion Criteria:
- Patients must meet the following inclusion criteria for the study: * Age ≥ 18 years and ≤ 85 years; * Patients with pancreatic cancer after radical resection or with advanced pancreatic cancer, who require further chemotherapy with the gemcitabine plus paclitaxel albumin-bound regimen; * ECOG performance status score of 0-2; * Normal hematological function (platelet count > 80×10⁹/L; white blood cell count > 3×10⁹/L; neutrophil count > 1.5×10⁹/L); * Serum bilirubin ≤ 1.5 times the upper limit of normal (ULN), and transaminase ≤ 5 times the ULN; * No ascites, no gastrointestinal obstruction, normal coagulation function, and serum albumin ≥ 30g/L; * Child-Pugh classification of liver function is Grade A; * Serum creatinine < ULN, or calculated creatinine clearance rate > 50ml/min.
Exclusion Criteria:
- Patients who meet any of the following criteria will be excluded from the study: * Local inflammation or infection of the auricleBleeding tendency or coagulation disorders; * Severe ascites; * Gastrointestinal obstruction; * Hypertensive crisis or hypertensive encephalopathy; * Severe uncontrolled systemic complications such as infection or diabetes mellitus; * Clinically severe cardiovascular diseases, including cerebrovascular accident (within 6 months before enrollment), myocardial infarction (within 6 months before enrollment), hypertension that is not well-controlled despite appropriate medication, unstable angina pectoris, congestive heart failure (NYHA Class 2-4), and cardiac arrhythmias requiring drug treatment; * A history of or physical examination findings indicating central nervous system diseases (e.g., primary brain tumor, epilepsy uncontrolled by standard treatment, any history of brain metastasis or stroke); * Hypersensitivity to any drugs used in the study; * Pregnant or lactating women; * Presence of any other diseases, functional impairment caused by metastatic lesions, or suspicious disorders identified during physical examination, which suggest contraindications to the study drugs or place the patient at high risk of treatment-related complications; * Inability or unwillingness to comply with the study protocol.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Auricular point stimulation group
For pancreatic cancer patients who will receive gemcitabine plus paclitaxel protein-bound for postoperative adjuvant or palliative chemotherapy, preventive antiemetic treatment consisting of unilateral auricular point stimulation at specific acupoints and dexamethasone will be administered within 30 minutes before chemotherapy.
Auricular acupoint stimulation is performed by adhering Vaccaria seeds to specific points with adhesive tape and applying moderate pressure until a certain level of soreness is elicited.
Vaccaria seeds are kept on the ear from the day of chemotherapy (Day 1) until the end of Day 5.
|
On the day of chemotherapy (Day 1): within half an hour before chemotherapy, administer auricular acupressure on one ear (stimulating the stomach, cardia, and brainstem acupoints for 5 minutes each) along with an intravenous push of 5 mg dexamethasone.
From the day of chemotherapy (Day 1) to the following five days (Day 1-Day 5): Stimulate each acupoint once in the morning, at noon, and in the evening, for 5 minutes each time.
If nausea or vomiting occurs, immediately apply additional stimulation for 5 minutes as a temporary measure.
Oral antiemetics should be prepared and may be used temporarily if nausea and vomiting are significant and the patient feels the need.
|
|
Aktiver Komparator: Standard pharmacologic antiemetic regimen group
Patients in the standard pharmacologic antiemetic regimen group will receive the standard pharmacologic antiemetic regimen chosen by their physicians according to clinical guidelines and patients' actual conditions.
|
Receive the standard pharmacologic antiemetic regimen chosen by their physicians according to clinical guidelines and patients' actual conditions, including dexamethasone ± 5-HT3 receptor inhibitor ± NK1 receptor inhibitor ± Olanzapine.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Anteil der Patienten, die Übelkeit erleben, bewertet nach NIC-CTC AE4.0
Zeitfenster: vom Tag der Chemotherapie (Tag 1) bis zum Ende von Tag 5
|
Die Teilnehmer werden gebeten, einen Fragebogen auszufüllen, um festzuhalten, ob Übelkeit auftritt.
Wenn Übelkeit auftritt, sollte ihr Schweregrad gemäß NIC-CTC AE4.0 erfasst werden.
|
vom Tag der Chemotherapie (Tag 1) bis zum Ende von Tag 5
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Anteil der Patienten, die Erbrechen erfahren, bewertet durch NIC-CTC AE4.0
Zeitfenster: vom Tag der Chemotherapie (Tag 1) bis zum Ende von Tag 5
|
Die Teilnehmer werden gebeten, einen Fragebogen auszufüllen, um festzuhalten, ob Erbrechen auftritt.
Wenn Erbrechen auftritt, soll dessen Grad gemäß NIC-CTC AE4.0 erfasst werden.
|
vom Tag der Chemotherapie (Tag 1) bis zum Ende von Tag 5
|
|
Anteil der Patienten, die zusätzliche Antiemetika benötigen
Zeitfenster: vom Tag der Chemotherapie (Tag 1) bis Tag 5
|
vom Tag der Chemotherapie (Tag 1) bis Tag 5
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Anteil der Patienten, die chemotherapiebedingte unerwünschte Ereignisse erleben, bewertet nach CTCAE v4.0
Zeitfenster: vom Tag der Chemotherapie (Tag 1) bis Tag 5
|
vom Tag der Chemotherapie (Tag 1) bis Tag 5
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Ermittler
- Studienstuhl: Juan Wang, Second Affiliated Hospital, School of Medicine, Zhejiang University
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Allgemeine Veröffentlichungen
- [1] CONROY T, PFEIFFER P, VILGRAIN V, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology, 2023, 34(11): 987-1002.[2] PUSCEDDU S, GHIDINI M, TORCHIO M, et al. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers, 2019, 11(4): [3] KIMURA S, HOSOYA K, OGATA K, et al. Severity of constipation related to palonosetron during first-line chemotherapy: a retrospective observational study. Support Care Cancer, 2021, 29: 4723-32.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
12. Dezember 2025
Primärer Abschluss (Geschätzt)
6. Dezember 2026
Studienabschluss (Geschätzt)
12. Dezember 2026
Studienanmeldedaten
Zuerst eingereicht
16. Juli 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
16. Juli 2026
Zuerst gepostet (Tatsächlich)
21. Juli 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
21. Juli 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
16. Juli 2026
Zuletzt verifiziert
1. Dezember 2025
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 20251947
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .